What is Claimed Is:

1. A potent non-neurotoxic antiischemic composition, highly effective by the intraperitoneal route of administration, in the treatment of both global and focal ischemia, and comprising as the active ingredient, an effective amount of an antiischemic Δ^2-1,2,3-triazoline compound, selected from the group consisting of those of the formulae,



wherein R^2 is 4-pyridyl, 3-pyridyl, or 2-pyridyl and R^1 is 3,4- or 3,5-dichloro, p- or m-chloro, p- or m-bromo, p- or m-fluoro, p- or m-trifluoromethyl, p- or m-lower alkyl, p- or m-lower alkoxy or hydrogen, and a pharmaceutical carrier.

2. A composition according to claim 1 wherein R^2 is 4-pyridyl and R^1 is hydrogen.

3. A composition according to claim 1 wherein R^2 is 4-pyridyl and R^1 is p-chloro.

4. A composition according to claim 1 wherein R^2 is 4-pyridyl and R^1 is 3,4-dichloro.

5. A composition according to claim 1 wherein R^2 is 4-pyridyl and R^1 is p-fluoro.

6. A composition according to claim 1 wherein R^2 is 4-pyridyl and R^1 is p-trifluoromethyl.

7. A composition according to claim 1 wherein R^2 is 4-pyridyl and R^1 is m-chloro.

8. A composition according to claim 1 wherein R^2 is 4-pyridyl and R^1 is p-bromo.

9. A composition according to claim 1 wherein R^2 is 4-pyridyl and R^1 is 3,5-dichloro.

10. A composition according to claim 1 wherein R^2 is 3-pyridyl and R^1 is m-chloro.

11. A composition according to claim 1 wherein R^2 is 3-pyridyl and R^1 is p-chloro.

12. A composition according to claim 1 wherein R^2 is 3-pyridyl and R^1 is hydrogen.

13. A composition according to claim 1 wherein R^2 is 2-pyridyl and R^1 is p-bromo.

14. A composition according to claim 1 wherein R^2 is 2-pyridyl and R^1 is p-chloro.

15. A non-neurotoxic antiischemic composition, effective by the intraperitoneal route of administration in the treatment of both global and focal ischemia, and comprising as the active ingredient an effective amount of an antiischemic triazoline compound, selected from the 2-oxo-1-pyrrolidino-Δ^2-1,2,3-triazoline group consisting of those of the formulae,



wherein R^1 is 3,4- or 3,5-dichloro, p- or m-chloro, p- or m-bromo, p- or m-fluoro, p- or m-trifluoromethyl, p- or m-lower alkyl, p- or m-lower alkoxy or hydrogen and a pharmaceutical carrier.

16. A composition according to claim 15 wherein R^1 is p-chloro, p-bromo or p-fluoro.

17. A composition according to claim 15 wherein R^1 is p-trifluoromethyl or m-trifluoromethyl.

18. A composition according to claim 15 wherein R^1 is 3,4-dichloro or 3,5-dichloro.

19. A composition according to claim 15 wherein R^1 is hydrogen.

20. A 2-oxo-1-pyrrolidino-Δ^2-1,2,3-triazoline compound of the following formulae,



wherein R^1 is 3,4- or 3,5-dichloro, p- or m-chloro, p- or m-bromo, p- or m-fluoro, p- or m-trifluoromethyl, p- or m-lower alkyl, p- or m-lower alkoxy or hydrogen.

21. A 2-oxo-1-pyrrolidino-Δ^2-1,2,3-triazoline compound according to claim 20 wherein R^1 is p-bromo or p-fluoro.

22. A 2-oxo-1-pyrrolidino-Δ^2-1,2,3-triazoline compound according to claim 20 wherein R^1 is m-chloro or 3,5-dichloro.

23. A 4-pyridyl methylamine compound of the following formulae,



wherein R^1 is p- or m-chloro, 3,4- or 3,5-dichloro, p- or m-bromo, p- or m-fluoro, p-methyl or methoxyl.

24. A 1-(4-pyridyl)-1-ethylamine compound of the following formulae,



wherein R^1 is 3,4- or 3,5-dichloro, 3,4- or 3,5-difluoro, p- or m-chloro, p- or m-bromo, p- or m-fluoro, p- or m-trifluoromethyl, p- or m-lower alkyl, p- or m-lower alkoxy or hydrogen.

25. A 1-(4-pyridyl)-1-ethylamine compound according to claim 24 wherein R^1 is 3,5-dichloro.

26. A 1-(4-pyridyl)-1-ethylamine compound according to claim 24 wherein R^1 is m-bromo, m-fluoro, m-trifluoromethyl, or 3,4-difluoro.

27. A 1-(3-pyridyl)-1-ethylamine compound of the following formulae,



wherein R^1 is 3,4- or 3,5-dichloro, p- or m-chloro, p- or m-bromo, p- or m-fluoro, p- or m-trifluoromethyl, p- or m-lower alkyl, p- or m-lower alkoxy or hydrogen.

28. A 1-(3-pyridyl)-1-ethylamine compound according to claim 27 wherein R^1 is p-chloro, p-bromo or 3,4-dichloro.

29. A 1-(4-pyridyl)-1-propylamine compound of the following form[illegible]



wherein R^1 is 3,4- or 3,5-dichloro, 3,4- or 3,5-difluoro, p- or m-chloro, p- or m-bromo, p- or m-fluoro, p- or m-trifluoromethyl, p- or m-lower alkyl, p- or m-lower alkoxy or hydrogen.

30. A 1-(3-pyridyl)-1-propylamine compound of the following formulae,



wherein R^1 is 3,4- or 3,5-dichloro, 3,4- or 3,5-difluoro, p- or m-chloro, p- or m-bromo, p- or m-fluoro, p- or m-trifluoromethyl, p- or m-lower alkyl, p- or m-lower alkoxy or hydrogen.

31. A α-phenyl-α-(4-pyridyl)methylamine compound of the following formulae,



wherein R^1 is 3,4 or 3,5-dichloro, p- or m-chloro, p- or m-bromo, p- or m-fluoro, m-trifluoromethyl, p-dimethylamino, p- or m-lower alkyl, p- or m-lower alkoxy or hydrogen.

32. A α-phenyl-α-(3-pyridyl)methylamine compound of the following formulae,



wherein R^1 is 3,4- or 3,5-dichloro, p- or m-chloro, p-bromo, m-trifluoromethyl, p-methyl, p-methoxy or hydrogen.

33. A α, α-bis-(2-pyridyl)methylamine compound of the following formula,



34. A non-neurotoxic antiischemic composition, effective by the intraperitoneal route of administration in the treatment of global ischemia and comprising as the active ingredient, an effective amount of an antiischemic compound selected from the group consisting of those of the formulae,



wherein R^2 is 4-pyridyl or 3-pyridyl, R^3 is hydrogen, methyl or ethyl, and R^1 is 3,4- or 3,5-dichloro, 3,4- or 3,5-difluoro, p- or m-chloro, p- or m-bromo, p- or m-fluoro, p- or m-trifluoromethyl, p- or m-lower alkyl, p- or m-lower alkoxy or hydrogen, and a pharmaceutical carrier.

35. A composition according to claim 34 wherein R^2 is 4-pyridyl, R^3 is hydrogen, methyl or ethyl, and R^1 is 3,4- or 3,5-dichloro.

36. A composition according to claim 34 wherein R^2 is 3-pyridyl, R^3 is hydrogen, methyl or ethyl, and R^1 is p-chloro, p-bromo, or 3,4-dichloro.

37. A composition consisting of an effective amount of an excitatory amino acid inhibitor (glutamate inhibitor) compound according to claim 1, claim 15 and claim 34 to yield an antiischemic composition effective against global and focal ischemia.

38. A composition according to claim 1, claim 15, claim 34 and claim 37, wherein a sufficient amount of the triazoline in claims 1, 15 and 20 or aminoalkylpyridine in claims 23, 24, 27, 29, 30, 31, 32 and 33 is contained in said composition to provide a dosage amount ranging from about 25 mg/kg to 200 mg/kg.

39. A method for the treatment of cerebral ischemia resulting from stroke in mammals, including man, which comprises administration thereto of an effective dosage amount of a triazoline or aminoalkylpyridine antiischemic composition of claim 1, claim 15, claim 34 and claim 37.

40. A composition according to claim 34 wherein R^2 is 3-pyridyl, R^3 is hydrogen, methyl or ethyl, and R^1 is p-chloro, p-bromo, or 3,4-dichloro.

41. A composition consisting of an effective amount of an excitatory amino acid inhibitor (glutamate inhibitor) compound according to claim 1, claim 15 and claim 34 to yield an antiischemic composition effective against global and focal ischemia.

42. A composition according to claim 1, claim 15, claim 34 and claim 37, wherein a sufficient amount of the triazoline in claims 1, 15 and 20 or aminoalkylpyridine in claims 23, 24, 27, 29, 30, 31, 32 and 33 is contained in said composition to provide a dosage amount ranging from about 25 mg/kg to 200 mg/kg.

43. A method for the treatment of cerebral ischemia resulting from stroke in mammals, including man, which comprises administration thereto of an effective dosage amount of a triazoline or aminoalkylpyridine antiischemic composition of claim 1, claim 15, claim 34 and claim 37.